A Phase II Study of Third-Line Combination Chemotherapy with Bevacizumab Plus S-1 for Metastatic Colorectal Cancer with Mutated KRAS (SAVIOR Study) | Zendy

Motoki Yoshida | Zendy; Akinori Takagane | Zendy; Yasuhiro Miyake | Zendy; Ken Shimada | Zendy; Naoki Nagata | Zendy; Atsushi Satō | Zendy; Yutaka Ogata | Zendy; Mutsumi Fukunaga | Zendy; Koki Otsuka | Zendy; Takao Takahashi | Zendy; Hidetomo Matsumoto | Zendy; Tatsuo Kagimura | Zendy; Akihito Tsuji | Zendy

Open Access

A Phase II Study of Third-Line Combination Chemotherapy with Bevacizumab Plus S-1 for Metastatic Colorectal Cancer with Mutated KRAS (SAVIOR Study)

Author(s) -

Motoki Yoshida,

Akinori Takagane,

Yasuhiro Miyake,

Ken Shimada,

Naoki Nagata,

Atsushi Satō,

Yutaka Ogata,

Mutsumi Fukunaga,

Koki Otsuka,

Takao Takahashi,

Hidetomo Matsumoto,

Tatsuo Kagimura,

Akihito Tsuji

Publication year - 2016

Publication title -

oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.987

H-Index - 98

eISSN - 1423-0232

pISSN - 0030-2414

DOI - 10.1159/000446372

Subject(s) - medicine , bevacizumab , oxaliplatin , irinotecan , colorectal cancer , gastroenterology , kras , chemotherapy , regorafenib , adverse effect , phases of clinical research , clinical endpoint , oncology , cancer , clinical trial

No salvage treatment had been established for metastatic colorectal cancer (mCRC) with mutated KRAS before the emergence of the new drugs regorafenib and TAS-102. We performed a phase II study of third-line chemotherapy with combined bevacizumab and S-1 for mCRC.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research